Free Trial

Veradigm (NASDAQ:MDRX) Shares Gap Down - Time to Sell?

Veradigm logo with Business Services background

Veradigm Inc. (NASDAQ:MDRX - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $4.70, but opened at $4.01. Veradigm shares last traded at $4.85, with a volume of 972 shares.

Analysts Set New Price Targets

Separately, Wall Street Zen started coverage on shares of Veradigm in a report on Tuesday, May 20th. They set a "hold" rating on the stock.

Check Out Our Latest Research Report on Veradigm

Veradigm Stock Up 3.2%

The firm's fifty day moving average is $4.41 and its 200-day moving average is $5.52.

Veradigm Company Profile

(Get Free Report)

Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

Read More

Should You Invest $1,000 in Veradigm Right Now?

Before you consider Veradigm, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.

While Veradigm currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines